AML is a devastating hematologic malignancy characterized by the rapid growth of abnormal white blood cells in the bone marrow, interfering with normal hematopoiesis. Among various genetic aberrations driving its aggressiveness, the internal tandem duplication (ITD) mutation in the FLT3 gene is associated with particularly poor prognosis. While targeted therapies, such as FLT3 inhibitors, have improved outcomes, resistance invariably arises, complicating long-term management. Cabozantinib, which inhibits multiple kinases including FLT3, has shown promise but is no exception to resistance development.

The team’s research pivots on the hypothesis that metabolic reprogramming—a hallmark of cancer—plays a critical role in how AML cells escape cabozantinib’s cytotoxicity. Using sophisticated cell models of FLT3-ITD AML, they meticulously charted changes in metabolic pathways as cells acquired drug resistance. By integrating multi-omic analyses including transcriptomics, metabolomics, and proteomics, they painted a comprehensive picture of the metabolic adaptations fueling survival under therapeutic pressure.

One of the most striking findings of the study is the shift in energy metabolism characterized by an enhanced reliance on oxidative phosphorylation (OXPHOS). Whereas sensitive AML cells predominantly utilize glycolysis for their energy demands, resistant cells exhibited a metabolic switch, increasing mitochondrial respiration to meet their bioenergetic needs. This adaptation not only supports survival but also grants cells metabolic flexibility, rendering them less susceptible to cabozantinib’s inhibitory effects on proliferative signaling.

Moreover, the researchers identified a pivotal rewiring of amino acid metabolism, particularly glutamine metabolism, which fuels the tricarboxylic acid (TCA) cycle and maintains redox balance in resistant cells. This metabolic flux supports the synthesis of critical biomolecules and antioxidants, helping cells withstand oxidative stress induced by cabozantinib. Elevated glutaminase activity emerged as a hallmark of resistance, suggesting that targeting glutamine metabolism could sensitize cells to treatment.

Furthermore, lipid metabolism was found to be substantially altered. Resistant AML cells showed increased fatty acid oxidation (FAO), which contributes not only to energy production but also to membrane biosynthesis and signaling molecules crucial for survival signaling pathways. This expansion of FAO creates an alternative metabolic reservoir that maintains cell viability in the face of kinase inhibition.

Building upon these insights, the authors explored therapeutic avenues aimed at reversing resistance by modifying the metabolic landscape. Pharmacologic inhibition of mitochondrial complex I, glutaminase, and fatty acid oxidation enzymes displayed significant synergistic effects when combined with cabozantinib, restoring drug sensitivity and inducing apoptosis in resistant AML cells. These findings point toward a multi-pronged metabolic intervention strategy that could preclude or overcome resistance.

Interestingly, the study also underscores the interplay between oncogenic signaling and metabolic regulation. FLT3-ITD signaling not only drives proliferation but also orchestrates metabolic gene expression programs that enable the metabolic plasticity observed in resistant cells. Interrupting this crosstalk disrupts AML cells’ adaptive capacity, highlighting the interconnectedness of genetic and metabolic vulnerabilities.

Importantly, this research emphasizes the utility of integrating comprehensive metabolic profiling in preclinical models to unveil resistance mechanisms that might otherwise remain obscured in genomics-focused approaches. By unraveling the metabolic dependencies of resistant AML cells, the study sets the stage for personalized metabolic interventions tailored to patients’ evolving tumor biology.

The translational value of these findings is substantial. Given that cabozantinib and metabolic inhibitors are already in clinical use or trials for various cancers, this study lays a practical framework for rapid clinical translation. Combination regimens guided by metabolic biomarkers have the potential to delay or abolish resistance, thereby prolonging remissions and improving survival outcomes for patients with FLT3-ITD AML.

Future research is warranted to evaluate the safety and efficacy of these metabolic combinations in vivo and in clinical trials. Equally important is the development of robust metabolic biomarkers to identify patients at risk of developing resistance and to monitor metabolic shifts during therapy. Such dynamic assessment will enhance the precision of therapeutic interventions and minimize unnecessary toxicities.

Finally, this study redefines our understanding of drug resistance in AML as a multifaceted phenomenon governed not only by genetic mutations but also by adaptive metabolic networks. Therapeutic strategies that incorporate metabolism-centric insights are poised to transform AML treatment and inspire analogous approaches in other malignancies characterized by targeted therapy resistance.

The pioneering work by Fu et al. demonstrates that it is possible to outmaneuver AML cells’ cunning metabolic reprogramming through strategic modulation of their metabolic signatures. This offers a beacon of hope for patients battling resistant AML, underscoring the power of deep mechanistic understanding to unlock new horizons in cancer therapy.

Subject of Research:
Acute myeloid leukemia (AML) with FLT3-ITD mutations and mechanisms of cabozantinib resistance.

Article Title:
Modulating metabolic signatures to mitigate cabozantinib resistance in FLT3-ITD acute myeloid leukemia cell models.

Article References:
Fu, YH., Ng, K.M., Tseng, CY. et al. Modulating metabolic signatures to mitigate cabozantinib resistance in FLT3-ITD acute myeloid leukemia cell models. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-02957-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-02957-8

Acute myeloid leukemia, a malignancy of hematopoietic progenitor cells, presents substantial clinical challenges due to its heterogeneity and therapeutic resistance. Despite advances in chemotherapy and hematopoietic stem cell transplantation, relapse rates remain high, underlining the urgent need for novel strategies. The investigation by Kalarestaghi et al. focuses sharply on how disrupting telomerase activity—an enzyme crucial for chromosomal end maintenance—and mitochondrial function can coalesce to augment programmed cell death in AML cells, thereby disrupting the cancer’s survival advantage.

Telomerase, a ribonucleoprotein complex, extends telomeres, the repetitive nucleotide sequences capping chromosomal termini. Its overexpression in most cancer cells, including AML, facilitates limitless replicative potential and genomic stability, hallmarks of malignancy. By contrast, normal somatic cells generally exhibit limited telomerase activity, making it an attractive, cancer-specific target. The study’s approach to inhibit telomerase disrupts this immortalization mechanism, priming leukemic cells for apoptotic signaling.

Parallel to telomerase inhibition, the researchers tackled mitochondrial functionality. Mitochondria, beyond their classical role in energy production via oxidative phosphorylation, serve as integrators of apoptotic pathways through regulation of membrane potential, reactive oxygen species generation, and release of pro-apoptotic factors. The mitochondrial dysfunction exploited in this research compromises the bioenergetic and redox balance of AML cells, thereby stressing their survival machinery and tipping the scales toward cell death.

Strikingly, the research revealed a synergistic interaction when telomerase inhibitors were combined with mitochondrial disruptors. This dual blockade amplified apoptotic induction beyond the additive effects observed when either pathway was inhibited alone. Molecular assays confirmed enhanced activation of intrinsic apoptotic markers, including cytochrome c release and caspase cascade engagement, validating the mechanistic underpinnings of this synergy.

The study employed a panel of AML cell lines, meticulously characterizing responses to treatment via viability assays, flow cytometry for apoptosis quantification, and mitochondrial membrane potential measurements. These comprehensive analyses demonstrated that the combined treatment sharply reduced cell viability while markedly increasing apoptosis, illustrating a potent anti-leukemic effect at the cellular level.

Importantly, the researchers utilized established pharmacological inhibitors known to target telomerase and mitochondrial respiratory complexes. This not only establishes a proof-of-concept for combined targeting but also opens the door for clinical translation, leveraging drugs with defined safety profiles or amenable to structural optimization. The molecular data indicate that mitigating mitochondrial respiration concurrently with telomerase suppression disrupts cancer cell metabolic flexibility, a critical adaptation for AML survival under stress.

Beyond cellular assays, the researchers explored downstream effects on survival signaling pathways. Suppression of telomerase and mitochondrial function dampened pro-survival factors like NF-κB and influenced mTOR signaling networks, which often confer resistance to chemotherapy. This multifaceted interference further destabilizes leukemic cells, increasing their susceptibility to apoptosis.

The innovation in this study lies not only in identifying dual vulnerabilities but also in elucidating the integrated stress responses AML cells experience under combinational inhibition. The resulting oxidative stress, energy deprivation, and DNA damage signal convergence accelerate irreversible apoptotic commitment, highlighting a sophisticated molecular interplay ripe for therapeutic exploitation.

Given these compelling findings, the research community is prompted to consider combination regimens involving telomerase and mitochondrial inhibitors as a next frontier in AML therapy. The substantial enhancement of apoptosis with dual intervention suggests potential for synergistic use alongside existing chemotherapeutics or targeted agents, possibly reducing drug resistance and minimizing adverse effects by allowing lower doses.

Furthermore, this work underscores the importance of metabolic and replicative immortality pathways’ convergence in cancer survival. Targeting these pathways simultaneously could disrupt cancer homeostasis more effectively than monotherapies, a concept that could extend beyond AML to other malignancies with shared dependencies on telomerase and mitochondrial function.

Future studies will inevitably focus on validating these findings in patient-derived xenograft models and clinical samples to establish translational relevance. Investigations might also refine the molecular mechanisms, such as delineating specific mitochondrial targets and telomerase isoforms implicated in resistance, guiding more precise drug development.

Moreover, integration of genomic and proteomic analyses may identify biomarkers predictive of response to combination therapy, facilitating personalized treatment strategies. This precision approach could maximize therapeutic windows and improve outcomes for AML patients with historically poor prognoses.

In summary, this breakthrough study by Kalarestaghi et al. exemplifies how exploiting the intricate interplay between telomerase activity and mitochondrial dynamics can yield potent apoptotic induction in AML cells. Their findings set a compelling precedent for further exploration of combined targeting strategies, heralding a promising horizon where the recalcitrance of AML may finally be overcome through molecularly informed therapeutic innovation.

Subject of Research: Combined targeting of telomerase and mitochondrial functions in acute myeloid leukemia cell lines, focusing on synergistic apoptosis induction.

Article Title: Combined Inhibition of telomerase and mitochondria synergistically promote apoptosis in AML cell lines.

Article References:
Kalarestaghi, H., Dizaji Asl, K., Mazloumi, Z. et al. Combined Inhibition of telomerase and mitochondria synergistically promote apoptosis in AML cell lines. Med Oncol 43, 5 (2026). https://doi.org/10.1007/s12032-025-03125-1

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12032-025-03125-1